Overview Performance Dividends Peer Group Options

(NKTR) Nektar Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6402681083

NKTR: Immunotherapy, Cancer, Autoimmune, Inflammatory, Dermatology

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company specializing in the discovery and development of immunomodulatory therapies for autoimmune diseases and cancer. Its pipeline includes NKTR-358, a regulatory T-cell (Treg) stimulator aimed at restoring immune balance in autoimmune disorders; PEG-CSF1, a modified colony stimulating factor targeting inflammatory resolution; a TNFR2 agonist designed for selective receptor activation without TNFR1 modulation; and NKTR-255, an IL-15 receptor agonist to enhance cancer immunotherapy. The company has established partnerships with major pharmaceutical firms, including Takeda, AstraZeneca, UCB, Roche, Pfizer, Amgen, Bristol-Myers Squibb, and Merck. Headquartered in San Francisco, Nektar was founded in 1990 and operates globally.

As of the latest data, NKTR is trading at $0.84 with a market capitalization of $146.87M. The stocks 20-day average volume is 3.25M shares. Its short-term moving averages (SMA 20: $0.83, SMA 50: $0.90) suggest near-term volatility, while the SMA 200 ($1.18) indicates a longer-term downtrend. The Average True Range (ATR) of $0.09 reflects moderate price fluctuations.

Based on and , NKTR is expected to trade in a range of $0.76 to $0.92 over the next three months. The stock may face resistance near the $0.90 level, aligning with its SMA 50, while support is likely around $0.76, considering its ATR and recent price action. Investors should monitor the companys pipeline progress and partnership developments for potential catalysts.

Additional Sources for NKTR Stock

News: Wall Street Journal Benzinga Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

NKTR Stock Overview

Market Cap in USD 128m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Pharmaceuticals
IPO / Inception 1994-05-03

NKTR Stock Ratings

Growth Rating -88.6
Fundamental -
Dividend Rating 0.0
Rel. Strength -60.7
Analysts 3.63/5
Fair Price Momentum 0.28 USD
Fair Price DCF -

NKTR Dividends

No Dividends Paid

NKTR Growth Ratios

Growth Correlation 3m -59.5%
Growth Correlation 12m -85.3%
Growth Correlation 5y -87.2%
CAGR 5y -51.31%
CAGR/Max DD 5y -0.52
Sharpe Ratio 12m -2.02
Alpha -84.65
Beta 2.821
Volatility 90.22%
Current Volume 3303.2k
Average Volume 20d 1905.4k
What is the price of NKTR stocks?
As of May 09, 2025, the stock is trading at USD 0.62 with a total of 3,303,246 shares traded.
Over the past week, the price has changed by -20.66%, over one month by +25.72%, over three months by -11.59% and over the past year by -62.26%.
Is Nektar Therapeutics a good stock to buy?
No, based on ValueRay Analyses, Nektar Therapeutics (NASDAQ:NKTR) is currently (May 2025) a stock to sell. It has a ValueRay Growth Rating of -88.64 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NKTR as of May 2025 is 0.28. This means that NKTR is currently overvalued and has a potential downside of -54.84%.
Is NKTR a buy, sell or hold?
Nektar Therapeutics has received a consensus analysts rating of 3.63. Therefor, it is recommend to hold NKTR.
  • Strong Buy: 2
  • Buy: 2
  • Hold: 3
  • Sell: 1
  • Strong Sell: 0
What are the forecast for NKTR stock price target?
According to ValueRays Forecast Model, NKTR Nektar Therapeutics will be worth about 0.3 in May 2026. The stock is currently trading at 0.62. This means that the stock has a potential downside of -46.77%.
Issuer Forecast Upside
Wallstreet Target Price 4.9 693.5%
Analysts Target Price 4.6 635.5%
ValueRay Target Price 0.3 -46.8%